163 results about "Phosphatidyl choline" patented technology

Compositions and methods useful in the non-surgical removal of localized fat deposits in patients in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion agents and pharmaceutically acceptable excipients but do not contain phosphotidylcholine. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.

The invention relates to a cucurbitacin liposome composition and its preparation, which has rather high encapsulation efficiency, and can be administered through vein, muscle, oral and nasal. The constituent percentage by weight of the composition are, cucurbitacin BE or cucurbitacin B 0.001-0.1%, phospholipids 0.1-10%, cholesterin 0-5%, the phospholipids can be lecithin, di-stearoyl phosphatidyl choline, di- palmityl phosphatidyl choline, di-oleoyl phosphatidyl choline, di- palmityl phosphatidyl ethanolamine, di-stearoyl phosphatidylglycerol. The preparation according to the invention can be prepared in the form of injection, oral liquid, syrup, drop and nasal spray

The invention relates to a method for preparing drug rehabilitation liposome agent, which comprises that using film disperse method or atomizing drying method to prepare long-circulation rehabilitation liposome, using cholesterol, distearin acyl phosphatidyl choline and myristate as stabilizers, using sucrose as freezing preservative, using chloroform and chloroform as organic solvents; and using amphipathic carbowax derivative to decorate the liposome membrane; and using compression or high-pressure homogeneity method to make the diameter of liposome smaller than 100nm and the package rate higher than 85%. The invention has less toxicity and high stability, as one novel drug slow-release target agent.

The invention relates to the technical field of medical diagnostics, in particular to a small molecule metabolite map for identifying liver cancer, hepatitis or liver cirrhosis and a manufacturing method thereof. The small molecule metabolites are four blood metabolites markers, i.e. palmitoyl hemolysis phosphoric acid ethanolamine glyceride, docosapentaenoic acyl hemolysis phosphatidyl choline, docosahexaenoic acyl hemolysis phosphatidyl choline and taurocholic acid, which respectively have the molecular weight of 453.2855, 569.3481, 567.3319 and 516.2916, and the corresponding ions of 454.2928, 570.3547, 568.3391 and 480.2776 detected through mass spectrum. Through experimentation on animals, the accuracy for determination of the liver cancer phase of a rat is 85 percent, and the accuracy for determination of the hepatitis or the liver cirrhosis is 94 percent. Clinical experiment results show that the accuracy for determination of the liver cancer is 85 percent, and the accuracy for determination of non-liver cancer is 71.9 percent. The method provided by the invention has the advantages of high sensitivity and high throughput, is superior to the existing liver cancer single diagnosis marker, and is applicable to screening and assisted diagnosis of the liver cancer.

The invention discloses a load small interfering RNA (siRNA) nanoscale lipid microbubble ultrasonic contrast agent and a preparation method. The load siRNA lipid microbubble is formed by preparing DPPC (Dipalmitoyl Phosphatidyl Choline), DSPE (1, 2-distearoyl-sn-glycero-3-phosphoethanolamine) and DPPA (Diphenyl Phosphoryl Azide) into microbubbles (containing octafluoropropane) according to the weight part ratio of 18:1:1 and then assembling together with PEG-PLL (Polyethylene Glycol-Polylysne)-coated siRNA nanomicelle. The load siRNA nanoscale lipid is nanosclae, has an obvious ultrasonic contrast effect, and can generate obvious siRNA cell transfection efficiency under low-frequency ultrasonic irradiation, thereby further hopefully having important research values and application prospects in the fields of ultrasonic diagnosis and gene treatment.

The invention relates to a method of preparing compounds, in particular to a method of preparing powder phosphatidylserine. The invention has to overcome the problems that the prior art inputs a lot of equipment and costs a lot, and the transformation ratio of the reaction is hard to be guaranteed. The invention has the technical proposal that a method of preparing powder phosphatidylserine takes natural lecithin as the reaction substrate; and after being separated by water, the reaction substrate can be added with an inorganic system prepared by L-serine, calcium salt and buffer solution to produce rough product under the effect of phospholipase D. Concentrate can be obtained by conducting the solvent extraction to the rough product, and then can be purified by solvent to obtain phosphatidylserine. The invention is characterized in that to separate the reaction substrate needs water three to ten times (w/v) of reaction substrate; and the separating temperature is ranged from 20 DEG C to 60 DEG C. In the system, the weight of the L-serine is two to ten times of the reaction substrate, and the weight of water used in the inorganic system is three to ten times(w/v) of reaction substrate. Ph value of the inorganic system can be adjusted between 4.5 and 6.0 by the buffer solution.

The present invention relates to compositions forming a low viscosity mixture of: a) 20-80 wt. % of at least one diacyl glycerol and/or a tocopherol; b) 20-80 wt. % of at least one phosphatidyl choline (PC); c) 5-20 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) up to 20 wt. % polar solvent e) at least one peptide active agent; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.

The invention belongs to the field of medicament preparations, and discloses an octreotide acetate lipidosome precursor and a preparation method thereof. The precursor lipidosome contains octreotide acetate, negatively-charged phospholipid and a cryoprotectant, and can contain an appropriate quantity of other lipids including phosphatidylchline and cholesterol; components such as an antioxidant, a pH regulating agent and the like can be added as required; the molar ratio of the octreotide acetate to the negatively-charged phospholipid is smaller than 1:1; and the mass ratio of the negatively-charged phospholipid to the cryoprotectant is 1:1-1:10. In the invention, a tert-butyl alcohol-water cosolvent freeze-drying method is adopted. The entrapment rate of an octreotide acetate lipidosome/micelle obtained by hydrating a freeze-dried product can be over 50 percent, an octreotide acetate lipidosome/micelle obtained by hydrating the freeze-dried product has high stability, and the problem of difficulty in entrapping a protein polypeptide medicament during preparation of a lipidosome/micelle preparation is solved. The preparation method is simple and practicable, and is suitable for industrial mass production.

The invention provides liposome injection of an amoxicillin sodium sulbactam sodium medicinal composition. The liposome injection consists of amoxicillin sodium, sulbactam sodium, liposome carriers, freeze-drying supporting agents and optional antioxidant, wherein the liposome carriers are dipalmitoyl phosphatidyl choline and deoxysodium cholate. The liposome injection has high stability; in the freeze-drying process, a phenomenon of breaking liposome caused by dehydration, fusion, ice crystal generation and the like does not occur; and the liposome can remain good encapsulation ratio after being hydrated and redissolved.

Chewing gum including a liquid center, a chewy layer surrounding the liquid center, and a coating surrounding the chewy layer. The liquid center includes a nanozome encapsulated dose of a cannabinoid such as cannabidiol of approximately 1-30 mg. The nanozome is preferably a phospholipid such as a Phosphatidyl Choline. In another embodiment the nanozome is unsaturated Phosphatidyl Choline to improve bioavailability of the cannabidiol, or other cannabinoid.

The present invention relates to a composition and a method for preparing a liposome, the liposome including a lipid bilayer and an aqueous core contains a hydrophobic or a hydrophilic drug and a component—Vitamin E derivative (d-α tocopheryl polyethylene glycol 1000 succinate; TPGS). TPGS is able to increase the encapsulation efficiency of drug in liposome as well as to enhance the stability of drug in liposomes. Such liposome is capable to increase the skin permeation of drugs. The preparation method comprises the following steps: (1) adding the drug to a Vitamin E derivative solution to form a mixture; and (2) adding at least one phosphatidyl choline to the mixture, after hydration from either sonication or homogenization.

The present invention relates to a goose liver paste and its production method. Said production method includes the following steps: respectively cooking the goose liver, soybean paste and nutrient additive, then uniformly mixing 30-70% of cooked goose liver, 15-45% of cooked soybean paste and 5-25% of cooked nutrient additive, cooling and packaging so as to obtain the invented product. The invented goose liver paste contains rich unsaturated fatty acid, phosphatide, phosphatidyl choline, glutamic acid, protein, amino acids and other nutrients necessary for human body.

The invention discloses a polyene phosphatidyl choline freeze dried injection for the treatment of hepatic diseases, which comprises polyene phosphatidyl choline as the main ingredients and pharmaceutically acceptable carrying agents, wherein the carrying agent can be auxiliary solvent selected from sodium cholate, sodium deoxycholate, sodium deoxycholate, hydroxypropyl-beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin and/or methyl cyclodextrin. The injection has higher stability.

The invention discloses a high-purity soya bean phosphatidyl choline without lysophosphatide preparing method in the phosphatide technique domain, which comprises the following steps: using soybean podwer phosphatide for raw material; extracting by dissolvant; freezing raffinate; treating liquor by dual column chromatogram; eluting for treating column 1; dislodging phosphatidyl ethanolamine; eluting and treating column2; dislodging lysophosphatide, wherein eluent of dissolvant,column 1 and column 2 for extracting is common single solvent; the production has no lysophosphatide; the bilineurine content of soya bean lecithin is more than 90%.

The invention discloses a method for preparing polyene phosphatidyl choline injection, including mixing polyene phosphatidyl choline, solubilizer, and injection water in proportion, stirring them into a colloidal dispersive system, adding in activated carbon to absorb, and adding proper antiseptic. It is a low-cost, simple-technique preparing method.

The invention provides a polyurethane material with side chain possessing fluorophosphatidylcholine and its preparation method, which is prepared through alternating copolymerization of a soft segment composed of polyether dihydroxy alcohol and/or polycarbonate diatomic alcohol and a rigid chain segment formed by diisocyanate and chain expanding agent, characterized in that the copolymer comprises the following repetition structural elements, wherein the partial rigid chain segment side chain contains fluorine-containing phosphatidyl choline groups, whose weight average molecular weight is 30000-60000.

The invention provides a method for synthesizing PE (Phosphatidyl Ethanolamine), which comprises the following steps of: (a) carrying out a reaction of a compound I and sodium azide to obtain a compound II; and (b) hydrogenating the compound II to obtain the PE. The invention has short synthesis path, simple and convenient operation, low cost, high yield and easy industrial production.

The invention provides a preparation method of a targeted temperature-controlled water-loading silibinin temperature-sensitive lipidosome-microbubble complex drug delivery system. The preparation method comprises the following steps of with single-palmitoyl phosphatidyl choline, dipalmitoyl phosphatidyl choline, distearoyl phosphatidyl ethanolamine-polyethylene glycol-amino and silibinin as raw materials, preparing water-loading silibinin temperature-sensitive lipidosome by virtue of a membrane rotary evaporation method; and coupling the water-loading silibinin temperature-sensitive lipidosome with an ultrasonic contrast agent, namely SonoVue microbubble, so as to prepare the targeted temperature-controlled water-loading silibinin temperature-sensitive lipidosome-microbubble complex drug delivery system. According to the preparation method, a new drug delivery system is established by combining the temperature-sensitive lipidosome with the microbubble; the efficient release of local tissues of a drug at a sub-high temperature field are achieved by virtue of the targeted explosion of the microbubble and the local temperature control effect of the temperature-sensitive lipidosome, so that the bioavailability of the drug is improved, and furthermore, residual tumors during thermal ablation treatment are reduced.

A pharmaceutical composition comprising (1) a compound that is converted to a glycosaminoglycan in a patient; (2) a primary antioxidant component; (3) at least one amino acid component; and (4) one or more of lecithin, phosphatidyl choline, or choline and methods for lowering blood pressure and/or pulse rate in a patient by administering to the patient the pharmaceutical composition.